E-cadherin 유전자의 단일 염기 다형성과 다형성이 전사의 조절에 미치는 영향에 관한 연구

Thesis(master`s)--서울대학교 대학원 :협동과정 종양생물학전공,2005.Maste

Simple and sensitive diagnosis of invasive aspergillosis using triphasic DE- ZnO-APDMS microparticle composite

The increasing mortality and incidence of invasive aspergillosis (IA) pose a serious threat to the health of immunocompromised populations. Herein, we synthesized triphasic microparticles named diatomaceous earthzinc oxide-3-aminopropyl(diethoxy)methylsilane (DE-ZnO-APDMS) for spores enrichment and fungal cell wall disintegration without detergents when incubated with Aspergillus fumigatus (A. fumigatus). Using the triphasic DE-ZnO-APDMS microparticles and PCR assays, we developed a simple and sensitive A. fumigatus diagnostic assay. In tests with cultured A. fumigatus samples, the diagnosis assay we presented has shown its superiority over commercial kit, including the ease of fungal cell wall disintegration, spores capture, and the isolation of fungal DNA during sample preparation. Furthermore, the clinical utility of the proposed fungal diagnostic assay in 30 clinical samples showed superior sensitivity (100 %) to the conventional kit (50 %). The developed DE-ZnOAPDMS-based fungal diagnostic assay is a potentially valuable tool for diagnosing and monitoring invasive aspergillosis

Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer

KRAS mutation is a major regulator in the tumor progression of pancreatic cancer. Here, we compared the frequency and mutation burden of KRAS mutation subtypes with paired tumor tissue and blood in patients and examined their clinical significance. DNA from tumor tissues and cell-free DNA (cfDNA) from preoperative blood were obtained from 70 patients with pancreatic cancer. Subtypes and mutation burdens of KRAS G12D and G12V mutations were evaluated using droplet digital PCR. Comparing the presence of mutations in tissue, accumulative and simultaneous mutations of G12D or G12V were identified of 67 (95.7%), and 48 patients (68.6%). Conversely, in blood, they were only identified in 18 (25.7%) and four (5.7%) patients; respectively. Next, comparing the mutation burden in tissue, the mutation burden varied from less than 0.1 to more than five, whereas that of cfDNA in blood was mostly between one and five, as cases with a mutation burden lower than 0.1 and higher than five were rare. Finally, the presence of the G12V mutation alone in cfDNA and the combination of the G12V mutation with elevated CA 19-9 levels were associated with poor recurrence-free survival. These fundamental data on the KRAS mutation subtypes and their clinical significance could support their potential as predictive markers for postoperative recurrence